This month, we are releasing an AHP quality improvement initiative for ADHD in patients ≤21 years of age. Recognizing that ADHD is complicated in terms of diagnosis, the impact of comorbidities, and multiple available treatment options, we have chosen to initially focus on rates of pediatric ADHD diagnosis and network-wide prescribing patterns of stimulant medications…
AHP will be distributing clinical integration payments for the fourth quarter of 2018 to contract-participating, community PCPs in March. Based on a provider’s member attribution under an AHP gain sharing contract, these payments are provided to support provider efforts to advance AHP’s clinical integration initiatives. Checks are scheduled to be mailed in late March. Also…
Excellus BlueCross BlueShield has contracted with Vatica Health to provide a web-based tool that increases the accuracy and completeness in coding of HCCs for Medicare Advantage members. AHP is encouraging primary care practices with significant Excellus Medicare Advantage attribution to consider implementing the Vatica program, since more accurate HCC coding may position AHP for additional…
We are always looking for new ways to connect with our partners, and sometimes a once-a-month newsletter just won’t get the job done! That’s why we invite you to look for AHP on Twitter and LinkedIn. With postings on healthcare news, job opportunities and upcoming events, following AHP will keep you even better informed about…
Please save the date for AHP’s next Clinical Grand Rounds scheduled for Thursday, March 28, 2019. The event will be held at the UR Alumni and Advancement Center at 300 East River Road, Rochester, NY from 5:00 to 8:00 pm. The meeting’s agenda is being finalized and will be included in the meeting invitation that…
The AHP Pharmacy Task Force works to identify opportunities that will enhance the quality, safety and value of medication treatment for our patients. Recently, we identified a cohort of patients across the PCN on duplicate therapy for Type 2 Diabetes with a GLP-1 agonist (e.g., Victoza, Trulicity, Byetta, Bydureon) and a DPP-4 inhibitor (e.g., Januvia,…
In 2018, we focused our efforts on a pharmacy inhaler initiative, requesting that prescribers, “Consider the use of either fluticasone/salmeterol RespiClick or Symbicort as “first line” in the ICS/LABA class.” We set an achievable network goal based on your feedback to decrease Advair Diskus/HFA’s market share from 54% in 2017 to 41% by March 2019….
As we continue to close out our data from 2018 we want to be able to provide you with the most accurate snapshot of our performance. This month we do not have a Population Health Dashboard to show, but can report that the network’s Triple Aim reports will be delivered in mid-March.
Rochester Lifestyle Medicine Institute (RLMI) has been awarded a grant by Accountable Health Partners to support 40 of their physicians attending a plant-based nutrition course and 200 of their patients going through a 15-Day Whole-Food Plant-Based Jumpstart. The purpose of the grant is to promote a team-centered approach to preventing, treating, and reversing lifestyle-related chronic…
As we had announced previously, we have been hard at work to create and get approval for our 2019 contract metrics for our Excellus contracts. As we have recently received final clarification of our population attribution for this year, we are ready to move forward with release of these metrics and publishing them in the…
